Clarithromycin was shown to be effective therapy for Treponena paUlidum infections in hamsters. Clarithromycin therapy was effective when initiated either 1 or 8 days after infection. The delay in initiation of therapy allowed an active infection to develop. The treponemal burden in lymph tissue of treated hamsters was eradicated, as determined by dark-field microscopy and by inoculation of lymph material into susceptible hamsters. Treatments with clarithromycin and the 14-hydroxy metabolite of clarithromycin were equally effective. Therapy with clarithromycin and penicillin was not antagonistic and did not appear to be synergistic when the two drugs were given concurrently. Pharmacokinetic evaluation of clarithromycin in hamsters showed that the doses which produced effective therapy yielded concentrations in serum similar to those routinely achieved in human sera. These findings demonstrate that clarithromycin is effective in treating active or incubating syphilis in the hamster model and could be useful in treating humans.
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While penicillin is still the drug of choice for the treatment of Treponema pallidum infection, there is a need for alternative therapies. There have been treatment failures with penicillin in human immunodeficiency virus-positive and AIDS patients (3, 5, 11, 14, 20, 21) , and some individuals have rapidly progressed to neurosyphilis despite normally adequate therapy (15, 23) . For penicillin-allergic patients, the choice of alternative therapy is limited to doxycycline or tetracycline, with erythromycin, ceftriaxone, or penicillin desensitization as alternatives in tetracycline-intolerant individuals (6) . Both tetracycline and erythromycin are given four times daily for 15 or 30 days, which frequently results in a lack of patient compliance or drug intolerance.
Macrolides have shown efficacy against T. pallidum, and erythromycin is recommended as an alternative treatment in penicillin-sensitive patients. Clarithromycin and erythromycin have identical mechanisms of action. Clarithromycin is a new macrolide antimicrobial drug with several distinct advantages over erythromycin, including improved gastrointestinal tolerance, an active 14-hydroxy metabolite, higher concentrations in serum and tissue, and a significantly longer terminal disposition half-life (12) . Other macrolides have also shown efficacy against T. pallidum infection in animal models (18, 19) . For these reasons, it was anticipated that clarithromycin could be effective against T. pallidum.
The efficacy of clarithromycin therapy was assessed by the eradication of treponemes from inguinal lymph nodes as indicated by a negative result in dark-field microscopy and by the inability of the lymph node material to infect susceptible hamsters. Serological results were also used as a measure of treponemal burden in the hamsters during treatments. Pharmacokinetic performance was used to correlate efficacy with concentrations of the drug in serum for a clinical environment.
MATERIALS AND METHODS Animals. Six-to eight-week-old male Syrian hamsters weighing 80 to 100 g were obtained from Charles River * Corresponding author.
Breeding Laboratories, Inc. (Wilmington, Mass.). These animals were free of major pathogens and did not have antitreponemal-antibody titers. All animals were fed antibiotic-free food and water and were housed at 21°C.
Organism. Treponema pallidum subsp. pertenue was maintained by passage in hamsters (28) . The treponemes were isolated from infected hamster lymph tissue and placed in RPMI 1640 supplemented with 10% fetal bovine serum, 10 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES), and 0.63 nM dithiothreitol. After centrifugation at 1,000 x g to remove cellular debris, the concentration of treponemes was determined by dark-field microscopy.
Infection of animals. Animals were randomly divided into groups of four or eight individuals. The inguinal-node regions of each animal were shaved and injected intradermally with 0.1 ml of treponemal suspension containing 107 virulent T. pallidum organisms per ml (106 T. pallidum organisms per site).
Antimicrobial therapy. Antimicrobial therapy was administered as follows: benzathine penicillin G, intramuscularly as a single dose 1 or 8 days following inoculation; clarithromycin, subcutaneously once or twice daily for 7 consecutive days (on days 1 through 7 or 8 through 14); or penicillin and clarithromycin combination therapy (on days 1 and 1 through 7 or 8 and 8 through 14).
Clarithromycin was provided by Abbott Laboratories (Abbott Park, Ill.) and was supplied as an oil-in-water emulsion to allow for subcutaneous dosing. The oil phase of the clarithromycin emulsion was prepared by dissolving 5 g of the drug in 20 g of soybean oil in the presence of 3 g of hexanoic acid and 6 g of oleic acid. The aqueous phase was prepared by dispersing 5 g of egg phosphatide in 500 ml of water with heat, to which 50 ml of 0.6 N aqueous sodium hydroxide and 25 g of glycerin were added. To obtain the emulsion, the aqueous phase was homogenized in a microfluidizer until it was semitransparent. The oil phase was slowly added with mixing. The resulting emulsion was processed in the microfluidizer to obtain a fine emulsion with a mean particle diameter of approximately 150 nm. After the pH of the emulsion was adjusted to 7.4 with aqueous sodium hydroxide, the volume was adjusted to 1,000 ml with water.
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The final emulsion was filtered through a 0.2-,um-pore-size nylon filter and stored at 5°C until used. The chemical stability of this emulsion at 5°C is greater than 2 years.
The benzathine penicillin G suspension for injection was obtained from Wyeth Laboratories, Philadelphia, Pa. Erythromycin and the 14-hydroxy metabolite of clarithromycin were provided by Abbott Laboratories.
Evaluation of T. paUlidum burden. At 35 days after inoculation, the inguinal lymph nodes were excised, cellular debris were pelleted at 1,000 x g, and the treponemal concentration in the supernatant was determined by darkfield microscopy as described previously (28, 29) . The sensitivity of this method was 5 x 104 treponemes per lymph node. As a test for latent infection, supematant fluid from the lymph node preparation was injected into susceptible hamsters. Four weeks after inoculation, lymph tissue from the hamsters was assayed for treponeme content and for serologic evidence of infection.
Serological evaluation. Upon termination of the trial, serum samples were obtained from the hamsters for serologic evaluation. The Sera-Tek hemagglutination kit was used according to the manufacturer's directions (Miles Inc., Elkhart, Ind.). This assay utilizes turkey erythrocytes coated with treponemal antigen to produce agglutination titers ranging from 0 (negative) to 4+ (strongly reactive).
Pharmacokinetics. The concentrations of clarithromycin, 14-hydroxy-clarithromycin, and erythromycin following a single subcutaneous dose (20 mg/kg of body weight) in hamsters were determined by bioassay (10 hamsters that yielded no detectable treponemes by dark-field microscopy failed to infect susceptible hamsters following inoculation (data not shown).
Combination trials with penicillin and clarithromycin. The ability of clarithromycin to significantly reduce treponemal burden in lymph tissue was not inhibited by a suboptimal (8) (9) (10) (11) (12) (13) (14) 0.0 ± 0.0C 10.0 mg BID (8) (9) (10) (11) (12) (13) (14) 0.0 ± 0.0C (8) (9) (10) (11) (12) (13) (14) 0.0 ± 0.0C Clarithromycin 10 mg BID (8) (9) (10) (11) (12) (13) (14) penicillin dosage regimen of a single 250-U/kg dose (Table 3) . Suboptimal doses of clarithromycin and penicillin did not appear to be antagonistic or synergistic in vivo. The titers in serum were similar for treatment groups that yielded no detectable treponemes by dark-field microscopy (data not shown). Once again, lymph material from hamsters that yielded no detectable treponemes by dark-field microscopy failed to infect susceptible hamsters following inoculation (data not shown). Assay for latent infection. Hamster lymph node material that was negative by dark-field microscopy for detectable treponemes was inoculated into susceptible hamsters as a test for latent infection. No treponemes were detected, nor was there serologic evidence of infection in any of the recipients of lymph node material that was negative by dark-field microscopy. In contrast, lymph node material that was positive for treponemes by dark-field microscopy produced an infection that was apparent by dark-field microscopy 4 weeks after inoculation into susceptible hamsters (data not shown). Pharmacokinetics. The results of pharmacokinetic evaluation of clarithromycin in hamsters are presented in Table 4 . Following equivalent 20-mg/kg doses, the maximum concentrations in serum (Cm.x) of clarithromycin and the 14- hydroxy metabolite were 2.1 and 1.5 ,ug/ml, respectively, while the half-life values were 4.11 and 1.69 h.
DISCUSSION
Clarithromycin therapy was curative at daily doses of 10.0 to 12.5 mg/kg and at twice-daily doses of 2.0 to 2.5 mg/kg. Daily doses of clarithromycin eradicated treponemal burden as evidenced by the lymph tissue both being negative by dark-field microscopy and failing to infect susceptible hamsters. The 14-hydroxy metabolite of clarithromycin showed similar efficacy against T. pallidum infection in hamsters. This metabolite was tested separately, since rodents do not produce the active 14-hydroxy metabolite of clarithromycin which is produced in humans. Curative results were obtained with doses of clarithromycin that produced concentrations of the drug in serum similar to those achieved in humans. For example, the plasma Cm. for clarithromycin in healthy humans given a 500-mg oral dose ranged from 2.1 to 3.3 ,ug/ml (11), compared with a mean Cm. of 2.1 ,ug/ml in hamsters given a 20-mg/kg dose. The areas under the timeconcentration curve from 0 to 24 h for hamsters in this study were similar to those in humans (8) .
Serologic data suggest that the treponemal burdens in hamsters during therapy with clarithromycin and with penicillin were similar since the titers did not differ, while untreated hamsters produced higher titers. Clarithromycin was most effective when given twice daily, which is the dosing schedule used most often in humans. There was no antagonism or synergy demonstrated when clarithromycin was given concurrently with penicillin.
Experimental T. pallidum subsp. pertenue infection of hamsters provides a suitable model for study of infection and drug therapy (1, 2, 16, 26, 27, 29, 30) . The lymph node is a target site for T. pallidum infection in the hamster, and intradermal inoculation results in lymph nodes which yield detectable numbers of T. pallidum by dark-field microscopy. Persistent latent infection may be demonstrated in these animals by transfer of infective lymph node material to susceptible normal hamsters. A delay in initiation of treatment until day 8 allows the establishment of active infection with T. pallidum. In addition, hamsters produce antitreponemal titers in serum in proportion to the severity of infection.
Clarithromycin has shown efficacy against opportunistic infections associated with AIDS, such as Toxoplasma gondii and Mycobacterium avium (4, 7, 9, 10, 17, 24, 25) . A resurgence of syphilis has occurred since 1986, in part because of a high incidence within the human immunodeficiency virus-infected population (14, 22, 23) . Clarithromycin, with better patient tolerance and twice-daily dosing, could lead to better patient compliance than erythromycin or tetracycline, both of which are given four times daily for treatment of syphilis. The superior tissue penetration and efficacy against other opportunistic infections make clarithromycin particularly useful in the treatment of AIDS patients.
